The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC).
Olugbenga Olanrele Olowokure
No relevant relationships to disclose
Ivan Dario Bedoya
No relevant relationships to disclose
Michelle Lynn Mierzwa
No relevant relationships to disclose
Maria Patricia Torregroza
No relevant relationships to disclose
Alok kumar Dwivedi
No relevant relationships to disclose
Jiang Wang
No relevant relationships to disclose
Milton T Smith
No relevant relationships to disclose
Nathan Schmulewitz
No relevant relationships to disclose
Stephen Kucera
No relevant relationships to disclose
Kyuran Ann Choe
No relevant relationships to disclose
Ross Ristagno
No relevant relationships to disclose
Steven Rudich
No relevant relationships to disclose
Jeffrey J. Sussman
No relevant relationships to disclose
Syed A Ahmad
No relevant relationships to disclose